23-Valent pneumococcal polysaccharide vaccine in HIV-infected Ugandan adults: 6-year follow-up of a clinical trial cohort

Watera, C., Nakiyingi, J., Miiro, G., Muwonge, R., Whitworth, J. A. G., Gilks, C.F. and French, Neil (2004) '23-Valent pneumococcal polysaccharide vaccine in HIV-infected Ugandan adults: 6-year follow-up of a clinical trial cohort'. AIDS, Vol 18, Issue 8, pp. 1210-1213.

Full text not available from this repository.

Abstract

23-Valent pneumococcal polysaccharide vaccine was previously reported to be ineffective in HIV-infected Ugandan adults. Prolonged follow-up of trial participants confirmed a persistent excess of all-cause pneumonia in vaccine recipients [hazard ratio (HR) 1.6; 95% confidence interval (CI) 1.0-2.4], but surprisingly a survival advantage favouring vaccination (HR 0.84; CI 0.7-1.0). An explanation for the improvement in survival in the face of excess morbid events is lacking; a role for vaccine in HIV care in Africa remains unlikely.

Item Type:	Article
Additional Information:	Research Letter. This article is available full text from the URL above.
Uncontrolled Keywords:	prophylaxis
Subjects:	WA Public Health > Health Problems of Special Population Groups > WA 395 Health in developing countries WC Communicable Diseases > Infection. Bacterial Infections > Bacterial Infections > WC 217 Pneumococcal infections WC Communicable Diseases > Virus Diseases > Acquired Immunodeficiency Syndrome. HIV Infections > WC 503 Acquired immunodeficiency syndrome. HIV infections WC Communicable Diseases > Virus Diseases > Acquired Immunodeficiency Syndrome. HIV Infections > WC 503.5 Complications
Digital Object Identifer (DOI):	https://doi.org/10.1097/00002030-200405210-00018
Depositing User:	Sarah Lewis-Newton
Date Deposited:	12 Mar 2012 14:47
Last Modified:	14 Dec 2021 14:46
URI:	https://archive.lstmed.ac.uk/id/eprint/2104

Statistics

View details

Actions (login required)

Edit Item